Kiniksa Pharmaceuticals International PLC
KNSA
View Detailed Chart
44.940USD
-1.100-2.39%
Close 03/24, 16:00（ET）Quotes delayed by 15 min
2.18BMarket Cap
92.41P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.39%
5 Days
-4.42%
1 Month
+3.31%
6 Months
+24.52%
Year to Date
+8.95%
1 Year
+91.97%
View Detailed Chart
TradingKey Stock Score of Kiniksa Pharmaceuticals International PLC
Currency: USD Updated: 2026-03-23Key Insights
Kiniksa Pharmaceuticals International PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 2 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 55.86.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kiniksa Pharmaceuticals International PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Kiniksa Pharmaceuticals International PLC Highlights
StrengthsRisks
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 92.22% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 94.67, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.91M shares, decreasing 10.64% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.15K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.07.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
55.857
Target Price
+21.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Kiniksa Pharmaceuticals International PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kiniksa Pharmaceuticals International PLC Info
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Ticker SymbolKNSA
CompanyKiniksa Pharmaceuticals International PLC
CEOPatel (Sanjiv K)
Websitehttps://www.kiniksa.com/
Related Instruments
-0.83%
+0.56%
-0.06%
+0.93%
+0.60%
+0.13%
+0.35%
-0.38%
+0.56%
+0.71%
+0.19%
+0.83%
+1.85%
+0.68%
-0.58%
0.00%
+0.40%
+0.70%
+0.61%
+1.01%Popular Symbols
251.640
+0.150 (+0.06%)
175.200
-0.440 (-0.25%)
70472.010
+408.820 (+0.58%)
301.050
+6.260 (+2.12%)
2148.140
+2.160 (+0.10%)
383.030
+2.180 (+0.57%)
4576.250
+105.750 (+2.37%)
88.219
+0.116 (+0.13%)
1.160
-0.000 (-0.02%)
158.792
+0.097 (+0.06%)
